KeyCorp Issues Positive Forecast for Certara (NASDAQ:CERT) Stock Price

Certara (NASDAQ:CERT) had its target price raised by KeyCorp from $15.00 to $18.00 in a research report released on Wednesday morning,Benzinga reports. They currently have an overweight rating on the stock.

Other analysts have also recently issued research reports about the stock. Stephens reiterated an “overweight” rating and set a $17.00 target price on shares of Certara in a research report on Thursday, February 27th. Barclays dropped their price objective on Certara from $13.00 to $11.00 and set an “equal weight” rating for the company in a report on Thursday, April 10th. William Blair restated a “market perform” rating on shares of Certara in a report on Thursday, February 27th. TD Cowen initiated coverage on Certara in a research note on Thursday, February 27th. They issued a “buy” rating and a $16.00 price target for the company. Finally, Robert W. Baird increased their price target on shares of Certara from $9.00 to $13.00 and gave the company a “neutral” rating in a research report on Friday, April 11th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $15.17.

Certara Stock Down 2.5 %

Shares of NASDAQ CERT opened at $13.53 on Wednesday. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $2.18 billion, a PE ratio of -67.65, a price-to-earnings-growth ratio of 9.29 and a beta of 1.64. The firm’s 50-day moving average is $11.62 and its 200-day moving average is $11.43. Certara has a 1 year low of $8.64 and a 1 year high of $17.94.

Institutional Investors Weigh In On Certara

A number of hedge funds have recently modified their holdings of the business. Versant Capital Management Inc increased its stake in Certara by 218.8% during the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company’s stock worth $27,000 after purchasing an additional 1,866 shares in the last quarter. Venturi Wealth Management LLC boosted its holdings in shares of Certara by 839.1% in the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock valued at $30,000 after buying an additional 2,509 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of Certara by 48.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock valued at $34,000 after buying an additional 1,047 shares during the period. Johnson Financial Group Inc. bought a new stake in shares of Certara during the fourth quarter worth $47,000. Finally, Blue Trust Inc. raised its holdings in shares of Certara by 20.9% during the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock worth $56,000 after acquiring an additional 822 shares during the period. Institutional investors and hedge funds own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.